iX Biopharma Ltd. (SGX:42C)

Market Cap	191.89M +735.5%
Revenue (ttm)	7.77M +30.3%
Net Income	-10.14M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,039,300
Average Volume	15,679,735
Open	0.2050
Previous Close	0.2000
Day's Range	0.1880 - 0.2100
52-Week Range	0.0150 - 0.2050
Beta	n/a
RSI	67.36
Earnings Date	Feb 4, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 35
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 42C

Financial Performance

In fiscal year 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.